Upadacitinib for Vitiligo
This trial will evaluate the safety and efficacy of upadacitinib in participants with non-segmental vitiligo.
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2023 Phase 3 trial • 613 Patients • NCT03086343
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Does the eligibility for this experiment extend to those aged 80 and above?
"According to the trial's requirements for participation, applicants must be 18 or older and no more than 65 years old."
Have there been any other clinical tests utilizing Upadacitinib?
"Upadacitinib was initially studied at AZ Arthritis and Rheum Assoc /ID# 143130 in 2015, with a total of 18329 trials concluding since then. At the moment, 21 active clinical studies are underway; many located in Irvine, California."
Is this an unprecedented clinical trial?
"Upadacitinib has been a subject of clinical research since 2015, when AbbVie first sponsored the drug's initial trial comprising 1629 patients. After its Phase 3 approval in that same year, 21 active trials have now opened up across 54 countries and 953 cities."
What risks have been associated with using Upadacitinib for treatment?
"Due to the data available from Phase 2 trials, our team at Power considers upadacitinib's safety rating as a 2 on a scale of 1-3. As this is an early trial stage, there has yet to be evidence supporting its efficacy."
Are there any opportunities remaining to participate in this investigation?
"According to the clinicaltrials.gov database, this medical study is not presently seeking participants - even though it was originally posted on June 16th 2021 and last updated August 3rd 2022. Fortunately, 58 other trials are now open for enrolment."
What is the target enrollment for this clinical experiment?
"This trial has ceased recruiting, having last been updated on August 3rd 2022. If you are looking for other clinical trials related to vitiligo or Upadacitinib there are 37 and 21 studies respectively that require patients."
What prerequisites must be fulfilled to participate in this investigation?
"This medical study is seeking 185 people with vitiligo that are of legal age and not older than 65."
What medical conditions are most commonly treated with Upadacitinib?
"Upadacitinib is routinely prescribed to patients in need of systemic therapy, particularly those with rheumatoid arthritis, methotrexate resistance, and unsatisfactory outcomes from traditional treatments."